J.Safra Asset Management Corp Celldex Therapeutics, Inc. Transaction History
J.Safra Asset Management Corp
- $1.54 Billion
- Q3 2025
A detailed history of J.Safra Asset Management Corp transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, J.Safra Asset Management Corp holds 40 shares of CLDX stock, worth $1,106. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40
Previous 235
82.98%
Holding current value
$1,106
Previous $4,000
75.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CLDX
# of Institutions
203Shares Held
68.3MCall Options Held
219KPut Options Held
238K-
Kynam Capital Management, LP Princeton, NJ6.1MShares$169 Million14.83% of portfolio
-
Wellington Management Group LLP Boston, MA5.23MShares$145 Million0.02% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$130 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.96MShares$109 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.82MShares$106 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.29B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...